1278 studies found for:    Kennedy's Disease
Show Display Options
Rank Status Study
1 Completed
Has Results
Dutasteride to Treat Spinal and Bulbar Muscular Atrophy (SBMA)
Conditions: Kennedy's Disease;   Spinal and Bulbar Muscular Atrophy
Interventions: Drug: Dutasteride;   Drug: Placebo
2 Not yet recruiting High Intensity Training in Patients With Spinal and Bulbar Muscular Atrophy
Conditions: Spinal and Bulbar Muscular Atrophy;   Healthy Subjects
Interventions: Other: Supervised high intensity training;   Other: Optional training;   Other: Control period;   Other: Unsupervised High intensity training
3 Unknown  Effect of Goserelin (Zoladex®) in Spinal and Bulbar Muscular Atrophy
Conditions: Spinobulbar Muscular Atrophy;   Kennedy's Disease
Interventions: Drug: Goserelin;   Procedure: Electrophysiologic study;   Procedure: tissue biopsy
4 Active, not recruiting Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer
Condition: Advanced, Androgen Receptor Positive Triple Negative Breast Cancer
Intervention: Drug: Enzalutamide
5 Recruiting Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors
Condition: Advanced Solid Tumours With Androgen Receptor Pathway as a Potential Factor
Intervention: Drug: AZD5312
6 Completed Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron Disease
Conditions: Spinal Muscular Atrophy;   Amyotrophic Lateral Sclerosis;   Spinobulbar Muscular Atrophy
Interventions: Drug: leuprolide;   Drug: testosterone
7 Completed Association of Polymorphisms in the Androgen Receptor Gene and Finasteride Response in Women With Androgenetic Alopecia
Condition: Androgenetic Alopecia
Intervention: Drug: Finasteride
8 Recruiting Genetic Polymorphism of the Androgen Receptor-Gene and Sexual Function in Middle Aged Women
Conditions: Libido;   Receptors, Androgen;   Polymorphism, Genetic;   Androgen Effect
Intervention:
9 Recruiting Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
Conditions: Advanced Epithelial Ovarian;   Recurrent Epithelial Ovarian;   Fallopian Tube;   Primary Peritoneal Carcinoma.
Intervention: Drug: Enzalutamide
10 Recruiting Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy
Condition: Spinal and Bulbar Muscular Atrophy
Interventions: Drug: BVS857;   Drug: Placebo
11 Recruiting Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)
Condition: Metastatic Breast Cancer
Intervention: Drug: Orteronel
12 Recruiting Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer With Correlative Assessment of Androgen Receptor Signaling
Condition: Prostate Cancer
Intervention: Drug: Enzalutamide
13 Suspended A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer
Condition: Prostatic Neoplasm
Intervention: Drug: EZN-4176
14 Recruiting Study of Hepatic Function in Patients With Spinal and Bulbar Muscular Atrophy
Conditions: Liver;   Motor Neuron Disease
Intervention:
15 Recruiting GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
Conditions: Estrogen Receptor Negative Breast Cancer;   Human Epidermal Growth Factor 2 Negative Carcinoma of Breast;   Triple Negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: cisplatin;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI;   Drug: GDC -0941
16 Recruiting A Phase II Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT)
Conditions: Pre-treated Postmenopausal Patients With ER/PgR-negative/AR-positive or ER;   and/or PgR-positive/AR-positive Metastatic Breast Cancer
Intervention: Drug: DHEA (Dehydroepiandrosterone)
17 Recruiting Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC) With Microtubule Directed Chemo or AR-directed Therapy
Condition: Prostate Cancer
Intervention: Procedure: Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) imaging
18 Not yet recruiting Androgen Deprivation Therapy in Advanced Salivary Gland Cancer
Condition: Salivary Gland Cancer
Interventions: Drug: bicalutamide + triptorelin;   Drug: Cisplatin + Doxorubicin;   Drug: Carboplatin + Paclitaxel
19 Completed Effect of Functional Exercise in Patients With Spinal Bulbar Muscular Atrophy
Condition: Motor Neuron Disease
Interventions: Behavioral: A functional exercise program;   Behavioral: A stretching exercise program
20 Terminated
Has Results
Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Nilutamide;   Drug: Dasatinib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years